PFE - Pfizer Inc.

NYSE - NYSE Delayed Price. Currency in USD
35.97
+0.25 (+0.70%)
At close: 4:00PM EDT

35.97 0.00 (0.00%)
After hours: 6:28PM EDT

Stock chart is not supported by your current browser
Previous Close35.72
Open35.68
Bid0.00 x 36900
Ask0.00 x 800
Day's Range35.63 - 36.03
52 Week Range31.67 - 39.43
Volume19,315,552
Avg. Volume21,730,788
Market Cap210.409B
Beta0.95
PE Ratio (TTM)9.99
EPS (TTM)N/A
Earnings DateN/A
Forward Dividend & Yield1.36 (3.83%)
Ex-Dividend Date2018-05-10
1y Target EstN/A
Trade prices are not sourced from all markets
  • TheStreet.com4 hours ago

    Trump Administration Ups Dose Of Shame As TV Drug Ad Policy Idea Moves Forward

    The pharma industry spent $3.45 billion on television ads in 2017 and none of those ads mentioned drug prices. The Trump administration wants to change that. In his Rose Garden speech earlier this month, President Trump suggested that direct-to-consumer ads include mandatory pricing information along with risk issues and other educational information.

  • Pfizer’s Quarterly Revenue Trend in Q1 2018
    Market Realist6 hours ago

    Pfizer’s Quarterly Revenue Trend in Q1 2018

    Pfizer (PFE) reported revenues of $12.9 billion for the first quarter, which was a 1% growth compared to $12.8 million in Q1 2017. The growth in revenues was driven by a strong performance of its Innovative Health segment, partially offset by lower sales of its Essential Health products.

  • Analyst Recommendations for Pfizer on May 22
    Market Realist7 hours ago

    Analyst Recommendations for Pfizer on May 22

    Wall Street analysts estimate that Pfizer’s (PFE) top line will increase 1% to $13.7 billion in the second quarter. For the second quarter, analysts estimate that Pfizer will report 3.5% growth in revenues to $13.4 billion compared to $12.9 billion in Q2 2017. Pfizer stock has risen 10.3% over the last 12 months but has fallen 1.2% year-to-date.

  • Pfizer’s Valuation as of May 22
    Market Realist7 hours ago

    Pfizer’s Valuation as of May 22

    Pfizer (PFE) reported a 1% growth in revenues to $12.9 billion in the first quarter compared to $12.8 billion in the first quarter of 2017. It surpassed Wall Street analysts’ estimate for EPS but missed the revenue estimate. It reported EPS of $0.77 on revenues of $12.9 billion compared to the EPS estimate of $0.74 on revenues of $13.1 billion.

  • Better Buy: AbbVie Inc. vs. Pfizer Inc.
    Motley Fool17 hours ago

    Better Buy: AbbVie Inc. vs. Pfizer Inc.

    Which big pharma stock wins in a head-to-head match-up?

  • How Are Tesaro’s Valuations and Cash Flows?
    Market Realistyesterday

    How Are Tesaro’s Valuations and Cash Flows?

    Tesaro used $147.6 million in operating activities in the first quarter—compared to $114.6 million in the first quarter of 2017. The company used $1.6 million in investing activities in the first quarter—compared to $1.8 million in the first quarter of 2017. The expense was mainly for purchasing property and equipment related to Tesaro expanding leased premises at its headquarters.

  • Tesaro Stock: What’s the Upside Potential?
    Market Realistyesterday

    Tesaro Stock: What’s the Upside Potential?

    Tesaro (TSRO) is a commercial stage biopharmaceutical company focused on developing treatments for solid tumors. Tesaro is licensed and developing a number of oncology-related product candidates. Of the 19 analysts covering Tesaro in May, 12 analysts gave the stock a “buy” or higher rating, while seven analysts gave a “hold” rating.

  • Why Did JNJ Scrap Its Alzheimer’s Drug Mid-Stage Trial?
    Market Realistyesterday

    Why Did JNJ Scrap Its Alzheimer’s Drug Mid-Stage Trial?

    Late last week, Johnson & Johnson (JNJ) announced that it was scrapping its mid-stage trial for the development of the treatment of Alzheimer’s disease, EARLY, which was in Phase 2b/3. The trial was testing the BACE inhibitor atabecestat. Johnson & Johnson is the latest in a series of companies, including Pfizer (PFE), Merck & Company (MRK), and Eli Lilly and Company (LLY), that have abandoned trials for their Alzheimer’s drug candidates.

  • Spark, Pfizer report progress on gene therapy for hemophilia
    American City Business Journalsyesterday

    Spark, Pfizer report progress on gene therapy for hemophilia

    The clinical testing program is expected to transition to Pfizer from Spark Therapeutics this summer.

  • Wall Street Sees Upside of More than 17% for JNJ in the Next Year
    Market Realistyesterday

    Wall Street Sees Upside of More than 17% for JNJ in the Next Year

    Over the last few quarters, Johnson & Johnson (JNJ) has seen a number of factors affecting investor sentiments surrounding its stock. The company, however, posted strong results for the first quarter on April 17, exceeding analysts’ estimates. In this article, we’ll take a look at analysts’ recommendations on JNJ for the next 12 months.

  • Gauging the Upside Potential of Vertex Pharmaceuticals Stock
    Market Realist2 days ago

    Gauging the Upside Potential of Vertex Pharmaceuticals Stock

    Vertex Pharmaceuticals (VRTX) is focused on developing and bringing to market therapies for treating cystic fibrosis (or CF) and advancing research and development programs for other diseases. Of the 25 analysts covering Vertex Pharmaceuticals in May, 21 of them have given the stock a “buy” or higher rating, and four have given it a “hold.” The mean rating for the stock is 1.76 with a target price of $191.39, implying an upside of 22.6% over its closing price of $156.16 on May 16. Of the 26 analysts covering Gilead Sciences (GILD) in May, 16 of them have given the stock a “buy” or higher rating, and ten have given it a “hold.” The mean rating for the stock is 2.15 with a target price of $85.81.

  • What’s Behind the 28% Hike in SCYNEXIS Stock Last Week?
    Market Realist2 days ago

    What’s Behind the 28% Hike in SCYNEXIS Stock Last Week?

    SCYNEXIS (SCYX) witnessed a 28% rise in its stock price in the week ended May 18. On May 18, SCYNEXIS stock closed at $1.63, which is ~14.4% growth from its previous close of $1.43 on May 17. SCYNEXIS stock rose ~27% over the last month. SCYNEXIS is a biotechnology company focused on the development of innovative therapies for the treatment of patients with difficult-to-treat and life-threatening infections.

  • A Look into Roche Holding’s Performance in Q1 2018
    Market Realist3 days ago

    A Look into Roche Holding’s Performance in Q1 2018

    In the first quarter, Roche Holding (RHHBY) reported revenues of ~13.6 billion Swiss francs compared to ~12.9 billion Swiss francs in the first quarter of 2017, which reflected ~5.0% growth on a YoY (year-over-year) basis.

  • Pfizer's Epilepsy Drug Lyrica Succeeds in Pediatric Study
    Zacks5 days ago

    Pfizer's Epilepsy Drug Lyrica Succeeds in Pediatric Study

    Pfizer (PFE) announces positive top-line results from a phase III study in pediatric epilepsy wherein Lyrica Oral Solution CV meets its primary endpoint.

  • Eli Lilly’s Valuation on May 17
    Market Realist5 days ago

    Eli Lilly’s Valuation on May 17

    Eli Lilly (LLY) reported EPS of $1.34 and revenues of $5.7 billion in the first quarter. Both results surpassed Wall Street analysts’ estimates.

  • Pharma Stock Roundup: Zoetis to Buy Abaxis, NVS Gets FDA Nod for Migraine Drug
    Zacks5 days ago

    Pharma Stock Roundup: Zoetis to Buy Abaxis, NVS Gets FDA Nod for Migraine Drug

    Novartis' (NVS) CGRP antibody, Aimovig gains FDA approval for prevention of migraine. Zoetis (ZTS) and Lilly (LLY) announce deals to buy smaller companies.

  • Exelixis Is Focused on Management of the Cabozantinib Franchise
    Market Realist6 days ago

    Exelixis Is Focused on Management of the Cabozantinib Franchise

    Exelixis (EXEL) is focused on the label expansion and life cycle management of the cabozantinib franchise in collaboration with Bristol-Myers Squibb (BMY) and Roche Holdings (RHHBY). The above diagram shows the rationale for studying cabozantinib in combination with immunotherapy in multiple cancer indications. Exelixis is currently evaluating the safety and preliminary activity, in terms of objective response rate and progression-free survival, of a combination of cabozantinib with nivolumab and a combination of cabozantinib with nivolumab and ipilimumab in advanced hepatocellular carcinoma (or HCC) indications in an ongoing Phase 2 trial.

  • Label Expansion May Boost Cabometyx’s Revenue in 2018
    Market Realist6 days ago

    Label Expansion May Boost Cabometyx’s Revenue in 2018

    On January 16, Exelixis (EXEL) and Ipsen announced positive results from the CELESTIAL Phase 3 trial highlighting the statistically significant and clinically meaningful improvement in the trial’s primary end point of overall survival due to cabozantinib therapy compared to a placebo in second-line and third-line hepatocellular carcinoma (or HCC) patients.

  • Cabometyx Is Expected to Witness a Robust Revenue Rise in 2018
    Market Realist6 days ago

    Cabometyx Is Expected to Witness a Robust Revenue Rise in 2018

    In the first quarter, Exelixis’s (EXEL) Cabometyx witnessed more than a 20% sequential rise in prescription volume driven by both new patient starts and a robust rise in the total number of patients on the therapy. According to a report, ~295,000 people across the world are diagnosed with kidney cancer every year, while 134,000 kidney cancer patients die every year. According to the American Cancer Society’s Cancer Facts & Figures 2018, the annual incidence of kidney cancer in the United States is ~65,000, while the annual death toll of the disease is 15,000. Another report estimates that almost 70%–75% of renal cell cancer (or RCC) patients suffer from clear cell RCC.

  • Financial Times6 days ago

    [$$] AstraZeneca chief Pascal Soriot suffers pay revolt

    suffered a significant revolt over the pay of its chief executive Pascal Soriot on Friday, when about 35 per cent of shareholders at its annual meeting voted against its remuneration report. Mr Soriot earned £9.4m in 2017, down from £14.3m a year earlier, but ISS had complained about the level of annual bonuses he had received, suggesting that the remuneration committee should have set more stringent targets. Pointing to the sales the company is garnering from its new medicines, one insider said that Mr Soriot was being “rewarded for turning science into products”.

  • Exelixis Focused on Positioning Cabometyx in Kidney Cancer Space
    Market Realist6 days ago

    Exelixis Focused on Positioning Cabometyx in Kidney Cancer Space

    Exelixis (EXEL) aims to position Cabometyx as the preferred tyrosine-kinase inhibitor (or TKI) in the renal cell carcinoma (or RCC) segment. At the end of 2017, Cabometyx had managed to acquire a 42% share of the second-line and new patient advanced RCC market, higher than its 39% market share at the end of the third quarter of 2017. Cabometyx demonstrated superiority over Pfizer’s (PFE) Sutent as a first-line RCC therapy in its Phase 2 CABOSUN trial in terms of progression-free survival, which has helped boost physicians’ confidence in Cabometyx.

  • InvestorPlace6 days ago

    Investors Need to Adopt a Different Mindset for Big Pharma and Biotech Stocks

    The ability to sell new drugs hinges on approvals from government bodies such as the Food and Drug Administration (FDA). As a result, biotech companies, and to some degree, large drug companies, go into business ventures without the certainty of ever earning revenues, let alone profits. Biotech stocks often become some of the most difficult to evaluate.

  • Sangamo Therapeutics Stock History
    Motley Fool6 days ago

    Sangamo Therapeutics Stock History

    After decades of research into gene editing, this biotech company could be on the cusp of developing game-changing new treatments for rare diseases.

  • Taking Stock of Gilead Sciences’ Key Developments
    Market Realist7 days ago

    Taking Stock of Gilead Sciences’ Key Developments

    During the first quarter, Gilead Sciences (GILD) entered into a scientific collaboration with Verily Life Sciences to identify and better understand the immunological basis of three common, serious inflammatory diseases—rheumatoid arthritis, inflammatory bowel disease, and lupus-related diseases—by making use of Verily’s Immunoscape platform.

  • Exelixis Is Expected to Report a Robust Revenue Rise in 2018
    Market Realist7 days ago

    Exelixis Is Expected to Report a Robust Revenue Rise in 2018

    The company reported net income of close to $115.9 million in the quarter, a YoY rise of ~594% and a sequential rise of 201%. Exelixis reported diluted GAAP (generally accepted accounting principles) EPS (earnings per share) of close to $0.37, a YoY rise of ~585% and a sequential rise of 201%. Analysts expect Exelixis to report revenue of close to $723 million in 2018, a YoY rise of ~59.8%.